1. Department of Medicine, Wilhelminenspital, Vienna, Austria;
2. Southwest Oncology Group, International Myeloma Foundation and Cedars Sinai Comprehensive Cancer Center, Los Angeles, CA;
3. Cancer Research and Biostatistics, Seattle, WA;
4. Department of Hematology, University Hospital, Malmö, Sweden;
5. Division of Hematology, Mayo Clinic, Rochester, MN;
6. Hematology Department, Institute of Hematology and Oncology, Hospital Clinic, Institut d' Investigacious Biomediques August Pi i Sunyer, Barcelona, Spain;
7. Division of Hematology and Oncology, Mayo Clinic Comprehensive Cancer Center, Scottsdale, AZ;
8. Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece;
9. Department of Medicine, Nagoya City Midori General Hospital, Nagoya, Japan;
10. University Hospital of Salamanca, Salamanca, Spain;
11. Department of Hematology, University Hospital, Lund, Sweden;
12. Division of Hematology, Centre Hospitalier Universitaire Hotel-Dieu, Nantes, France;
13. Department of Microbiology and Clinical Microbiology, Ankara University School of Medicine, Ibn-i Sina Hospital, Ankara, Turkey;
14. Divisione Universitaria di Ematologia, Ospedale Molinette, Torino, Italy;
15. Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR;
16. Department of Medicine, McGill University, Montreal, QC;
17. Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Bologna, Italy;
18. Institute of Haematology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia;
19. Service d'Hématologie, Hôpital Purpan, Toulouse, France; and
20. Department of Hematology, Erasmus MC, Rotterdam, The Netherlands